AU2001286965A1 - Sodium channel modulators - Google Patents

Sodium channel modulators

Info

Publication number
AU2001286965A1
AU2001286965A1 AU2001286965A AU8696501A AU2001286965A1 AU 2001286965 A1 AU2001286965 A1 AU 2001286965A1 AU 2001286965 A AU2001286965 A AU 2001286965A AU 8696501 A AU8696501 A AU 8696501A AU 2001286965 A1 AU2001286965 A1 AU 2001286965A1
Authority
AU
Australia
Prior art keywords
sodium channel
channel modulators
modulators
sodium
channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001286965A
Inventor
Jason P. Chinn
Seok-Ki Choi
Paul R. Fatheree
Daniel Marquess
S. Derek Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Advanced Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc filed Critical Advanced Medicine Inc
Publication of AU2001286965A1 publication Critical patent/AU2001286965A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001286965A 2000-08-31 2001-08-30 Sodium channel modulators Abandoned AU2001286965A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22957200P 2000-08-31 2000-08-31
US60/229,572 2000-08-31
PCT/US2001/027128 WO2002018334A2 (en) 2000-08-31 2001-08-30 Sodium channel modulators

Publications (1)

Publication Number Publication Date
AU2001286965A1 true AU2001286965A1 (en) 2002-03-13

Family

ID=22861810

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001286965A Abandoned AU2001286965A1 (en) 2000-08-31 2001-08-30 Sodium channel modulators

Country Status (3)

Country Link
US (2) US6756400B2 (en)
AU (1) AU2001286965A1 (en)
WO (1) WO2002018334A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6646012B2 (en) * 2001-01-16 2003-11-11 Theravance, Inc. Sodium channel modulators
WO2004066987A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
JP2006515327A (en) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド Methods for treating lower urinary tract disorders using sodium channel modulators
CN1829519A (en) * 2003-07-24 2006-09-06 默克公司 Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
US7060723B2 (en) * 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US7125908B2 (en) * 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US8058304B2 (en) 2004-04-01 2011-11-15 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US7977373B2 (en) 2004-04-01 2011-07-12 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
US7825265B2 (en) 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
AU2005240609A1 (en) * 2004-05-04 2005-11-17 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptor
WO2005115367A2 (en) * 2004-05-20 2005-12-08 The Regents Of The University Of California Modulation of neurotransmitter activity in neurons
US7531523B2 (en) * 2005-02-17 2009-05-12 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
AU2006223508A1 (en) * 2005-03-09 2006-09-21 Merck Frosst Canada Ltd Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
WO2007086895A2 (en) * 2005-03-22 2007-08-02 Pinnacle Pharmaceuticals Antibacterial compounds and uses thereof
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
AU2006327245A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation
US9862667B2 (en) * 2008-07-02 2018-01-09 The University Of British Columbia Diglycidic ether derivative therapeutics and methods for their use
AR079975A1 (en) * 2010-01-06 2012-03-07 British Columbia Cancer Agency THERAPEUTIC AGENTS DERIVED FROM BISPHENOL OR METHODS FOR USE, PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
CA2786319C (en) 2010-01-06 2019-03-12 British Columbia Cancer Agency Branch Bisphenol derivatives and their use as androgen receptor activity modulators
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
ES2680246T3 (en) * 2013-03-04 2018-09-05 Purdue Pharma Lp Pyrimidinecarboxamides as sodium channel blockers
KR101739800B1 (en) 2013-05-10 2017-05-25 브리티쉬 콜롬비아 캔써 에이전시 브랜치 Ester derivatives of androgen receptor modulators and methods for their use
US9375496B2 (en) 2013-09-09 2016-06-28 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
EP3988541B1 (en) 2015-01-13 2024-06-26 British Columbia Cancer Agency Branch Heterocyclic compounds for cancer imaging and treatment and methods for their use
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
EP3867216A4 (en) 2018-10-18 2022-07-13 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
EP4135675A4 (en) 2020-04-17 2024-04-10 Essa Pharma, Inc. Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1219039B (en) * 1959-09-26 1966-06-16 Bayer Ag Process for the production of primary diamines
US3197434A (en) * 1960-03-17 1965-07-27 Monsanto Co Polycarbonamides from organic dicarboxylic acids and bis(aminopropoxyaryl)alkanes and process for producing the same
FR150M (en) 1963-07-24 1961-01-20 Corbiere Et Pansements Brevete New product with local anesthetic action.
BE613143A (en) * 1961-01-27 1962-07-26 Ciba Geigy New phenoxy-ethers and process for their preparation
US3247199A (en) 1961-01-27 1966-04-19 Ciba Geigy Corp Diphenyl-methanes
US3340146A (en) * 1964-04-27 1967-09-05 Ciba Geigy Corp Taeniacidal compositions of bis-arylsulfides
US3449418A (en) * 1965-12-22 1969-06-10 Ciba Geigy Corp Etherified bisaryl compounds
US3598866A (en) * 1969-06-16 1971-08-10 Dow Chemical Co Adducts of alkenyl isocyanates with bisphenol a and derivatives thereof
US4008265A (en) * 1971-05-22 1977-02-15 Sumitomo Chemical Company, Limited Novel bisphenoxy carboxylic acid derivatives and their salts
JPS557861B2 (en) * 1972-10-04 1980-02-28
GB1584428A (en) * 1976-08-31 1981-02-11 Lilly Co Eli Herbicides
JPH06239815A (en) * 1993-02-16 1994-08-30 Teijin Ltd 2-aminoethoxybenzene derivative and medicinal composition
GB9403639D0 (en) * 1994-02-25 1994-04-13 Boots Co Plc Therapeutic agents
US5688830A (en) * 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
CA2232147A1 (en) 1997-04-03 1998-10-03 F. Hoffmann-La Roche Ag Phenoxymethyl piperidine derivatives
US6579328B2 (en) * 2000-05-01 2003-06-17 Ciba Specialty Chemicals Corporation Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines

Also Published As

Publication number Publication date
US20040204460A1 (en) 2004-10-14
US7183323B2 (en) 2007-02-27
US6756400B2 (en) 2004-06-29
WO2002018334A2 (en) 2002-03-07
US20030027822A1 (en) 2003-02-06
WO2002018334B1 (en) 2002-09-26
WO2002018334A3 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU2001286965A1 (en) Sodium channel modulators
AU2001276031A1 (en) Branded channel
AU2001253535A1 (en) Channel dancer
AU2002231325A1 (en) Stat modulators
AU2001264879A1 (en) Electrochromic devices
AU2001287983A1 (en) Seal system
AU2001281997A1 (en) Glazing
AU2002236775A1 (en) Sodium channel modulators
AU2000235960A1 (en) Lxr modulators
AU2001295758A1 (en) Seal
AU2001210076A1 (en) Ferrule seal
AU2001291854A1 (en) Antibacterials mutilins
AU4537400A (en) Ion channel modulating agents
EP1368891B8 (en) Iq modulator
AU2001266204A1 (en) Eyewear
AU2001265329A1 (en) Enhanced channel adapter
HUP0600032A2 (en) Sodium channel modulators derived from 2-piperidylimidazoles
AU5028201A (en) Seal arrangement
AU2001223878A1 (en) Sealant
AU4620300A (en) Can
AU2002221890A1 (en) Effect light
AU4087401A (en) Communications
AU2001256507A1 (en) Modulation
AU2001272594A1 (en) Sealing arrangement
AU2001267554A1 (en) Glazing